Study outcomes.
VIRUS, VIRAL SHEDDING
The primary objective of the study was to evaluate the antiviral activity of bemnifosbuvir compared with placebo through a change from baseline in the amount of nasopharyngeal SARS-CoV-2 viral RNA by RT-PCR at specified time points (days 3, 5, and 7). Secondary virologic endpoints were time to cessation of viral shedding (TCVS) measured by RT-PCR, defined as the time between the initiation of any study treatment and the first time a negative qualitative or BLQ (below the limit of quantification of 120 copies/mL) RT-PCR test result was obtained; time to sustained nondetectable virus RNA, defined as the time between initiation of any study treatment and the first time a negative qualitative or BLQ RT-PCR test result was obtained after which no positive quantitative test above or equal to the limit of quantification (LOQ) was reported; proportion of patients positive for virus RNA by RT-PCR, defined as the percentage of patients with a positive quantitative RT-PCR test result above or equal to the LOQ at each time point; and area under the curve (AUC) of virus RNA by RT-PCR. Exploratory virologic endpoints based on infectious virus measured by tissue culture infectious dose (TCID